News

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...
The Pharma Letter4h
ASCO: Positive Phase III results for Arvinas and Pfizer's vepdegestrant
Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...
Nasdaq2d
Arvinas and Pfizer Announce Phase 3 VERITAC-2 Trial Results Showing Vepdegestrant Improves Progression-Free Survival in ESR1-Mutant Breast Cancer Patients
and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...
Arvinas Shares Sink After Breast Cancer Treatment Didn't Improve Survival in Intent-to-Treat Population
Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that ...
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2
Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) announced Saturday their plans to submit a new drug application with the Food and ...
BioPharma Dive2d
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer
While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...
Devdiscourse21h
Breakthroughs in Breast Cancer and COVID Vaccines: Health News Highlights
Recent health news includes a promising AstraZeneca pill for breast cancer treatment, Pfizer and Arvinas' experimental drug ...
Devdiscourse2d
Breakthrough Breast Cancer Treatment by Pfizer and Arvinas Outshines Rival
Clinical trial results reveal an experimental treatment by Pfizer and Arvinas that delays breast cancer progression by over ...
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm
Breast cancer (BC) is the most prevalent cancer among women globally with two million diagnosed cases each year. Oestrogen ...
Morningstar2d
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...